- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.10. | CytoMed Therapeutics' chairman increases effective holdings to 21.95% | 1 | Seeking Alpha | ||
| 22.10. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95% | 1 | GlobeNewswire (USA) | ||
| 22.10. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.10. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.10. | CytoMed reports promising preclinical results for leukemia treatment | 1 | Investing.com | ||
| CYTOMED THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.10. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center | 2 | GlobeNewswire (USA) | ||
| 30.09. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.08. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.08. | CYTOMED THERAPEUTICS LIMITED: Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition | 346 | GlobeNewswire (Europe) | SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 19.08. | CytoMed Therapeutics plans to raise ~$4.3M via ATM offering | 1 | Seeking Alpha | ||
| 19.08. | CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program | 1 | GlobeNewswire (USA) | ||
| 19.08. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 21.07. | CYTOMED THERAPEUTICS LIMITED: Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or ... | 175 | GlobeNewswire (Europe) | SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based... ► Artikel lesen | |
| 21.07. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.07. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.06. | CytoMed Therapeutics files $50M mixed shelf offering | 3 | Seeking Alpha | ||
| 16.05. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 28.04. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates | 116 | GlobeNewswire (Europe) | SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 06.02. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders | 174 | GlobeNewswire (Europe) | SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board... ► Artikel lesen | |
| 06.01. | CytoMed Therapeutics In Collaboration Deal With India's SunAct Cancer Institute | 410 | AFX News | NEW DELHI (dpa-AFX) - Singapore-based CytoMed Therapeutics Ltd. (GDTC) announced Monday that it has entered into a Business & Research Collaboration Agreement or BRCA with SunAct Cancer Institute... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,80 | +0,17 % | Novartis will US-RNA-Spezialisten Avidity für zwölf Milliarden US-Dollar kaufen | BASEL (dpa-AFX) - Der Pharmakonzern Novartis will den US-RNA-Spezialisten Avidity für zwölf Milliarden US-Dollar kaufen. Pro Aktie sollen 72 Dollar bezahlt werden, wie das schweizerische Unternehmen... ► Artikel lesen | |
| QIAGEN | 40,760 | +0,90 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| CABALETTA BIO | 3,625 | +47,66 % | Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials | ||
| RECURSION PHARMACEUTICALS | 5,500 | -2,31 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 8,560 | +1,66 % | Morning Market Movers: Ventyx Biosciences, Brera Holdings, Safe & Green Holdings, American Rebel Holdings See Big Swings | CANBERA (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,185 | +52,80 % | Rani Therapeutics schließt Privatplatzierung ab und besetzt Vorstand neu | ||
| BIONTECH | 90,40 | +0,22 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| DYNE THERAPEUTICS | 22,580 | -4,08 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| BEAM THERAPEUTICS | 24,995 | +5,09 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| IMMUNOVANT | 24,700 | -0,44 % | Immunovant gains amid takeover speculation | ||
| ARCUTIS BIOTHERAPEUTICS | 25,320 | +1,61 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 81,40 | +3,75 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,900 | +1,45 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 33,320 | +3,25 % | Structure Therapeutics stock rating reiterated at Piper Sandler ahead of key data |
CYTOMED THERAPEUTICS LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,170 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTOMED THERAPEUTICS LIMITED finden Sie auf Wallstreet Online.